Search results
Results from the WOW.Com Content Network
F. Hoffmann-La Roche AG, commonly known as Roche (/ r ɒ ʃ /), is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company , Roche Holding AG , has shares listed on the SIX Swiss Exchange .
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [6]
The acquisition price was reduced to $204 million after federal officials issued subpoenas in an investigation of Medicare billing practices. [ 11 ] [ 12 ] [ 13 ] In April 1995, Hoffmann-La Roche , a division of Roche , contributed Roche Biomedical Laboratories, Inc. and US$186.7 million in cash to National Health Laboratories Holdings, in ...
Roche is open to making big acquisitions if they make "sense", Chief Executive Thomas Schinecker said, with the Swiss drugmaker unencumbered by its $20.7 billion deal last year to buy back its ...
ZURICH/FRANKFURT (Reuters) -Roche on Monday said it will buy Telavant, a developer of a new treatment for inflammatory bowel diseases, for an initial $7.1 billion from U.S biotech firm Roivant ...
Roche had paid $1.9 billion for New-York based Flatiron Health in 2018 to speed its development of cancer medicines and support its efforts to price them based on how well they work. The ...
454 Life Sciences was founded by Jonathan Rothberg [2] and was originally known as 454 Corporation, a subsidiary of CuraGen. For their method for low-cost gene sequencing, 454 Life Sciences was awarded the Wall Street Journal's Gold Medal for Innovation in the Biotech-Medical category in 2005. [3]
Roche expects data from this additional cohort in the second half of 2024. In December, Roche agreed to acquire a privately held obesity company, Carmot Therapeutics, for $2.7 billion in cash.